CoChat

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Open access
Engelbrechtsen, L., Lundgren, J., Wewer Albrechtsen, N. J., Mahendran, Y., Iepsen, E. W., Finocchietto, P., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T., Torekov, S. S. · 2017 · Obesity Science & Practice
Cited by 31

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Summary: Background: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on plasma lipid profiles and apoB. Methods: Fifty‐eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m 2 [mean ± SD]) were included in this study. After 8 weeks on a very low‐calorie diet (800 kcal/day), participants were randomized to weight maintenance with meal replacements with or without liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss and after 1 year of weight maintenance were subjected to nuclear magnetic resonance‐based lipidomics analysis. Results: After an 8‐week low‐calorie diet, study participants lost 12.0 ± 2.9 kg (mean ± SD) of their body weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly), including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol, triglycerides, low‐density lipoprotein and very low‐density lipoprotein subclasses. After 1 year of maintained weight loss, the majority of the lipids had returned to pre‐weight loss levels even though weight loss was successfully maintained in both groups. Interestingly, apoB levels remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02). Conclusion: An 8‐week low‐calorie diet, in individuals with obesity, reduced plasma levels of lipids and the atherogenic marker apoB. After 1 year of weight maintenance, only study participants treated with liraglutide maintained reduced levels of apoB, despite similar body weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and thus reflect lower CVD risk. Including apoB measurements in clinical practice when monitoring patients with dislipidemia or CVD might prove to be useful.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/osp4.133

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 29

  1. 10.1210/jc.2015-3213 · DOI
  2. Knight JA, 2011, Diseases and disorders associated with excess body weight, Ann Clin Lab Sci., 41, 107
  3. 10.3390/nu5041218 · DOI · Paper page
  4. 10.1016/0009-8981(73)90375-6 · doi:10.1016/0009-8981(73)90375-6
  5. 10.1093/qjmed/hcp065 · DOI
  6. 10.1016/S0140-6736(01)07098-2 · DOI · Paper page
  7. 10.1161/01.ATV.0000035521.22199.C7 · DOI · Paper page
  8. Elovson J, 1988, Plasma very low density lipoproteins contain a single molecule of apolipoprotein B, J Lipid Res., 29, 1461, 10.1016/S0022-2275(20)38425-X · DOI · Paper page
  9. 10.1046/j.1365-2796.2003.01276.x · DOI · Paper page
  10. 10.1007/s11745-002-1010-3 · DOI
  11. 10.1016/S0140-6736(10)60484-9 · DOI · Paper page
  12. 10.1016/j.ahj.2004.07.009 · DOI · Paper page
  13. 10.1007/BF00274216 · DOI · Paper page
  14. 10.1093/oxfordjournals.aje.a010233 · DOI · Paper page
  15. 10.1111/j.1463-1326.2011.01357.x · DOI · Paper page
  16. 10.1002/phar.1507 · DOI · Paper page
  17. 10.1586/14779072.2015.1054810 · DOI · Paper page
  18. 10.2337/dc09-S315 · DOI · Paper page
  19. 10.1161/ATVBAHA.115.305479 · DOI
  20. 10.1007/s00125-009-1611-5 · DOI · Paper page
  21. 10.1039/b910205a · DOI · Paper page
  22. 10.1111/j.1365-2796.2012.02562.x · DOI · Paper page
  23. 10.1161/CIRCGENETICS.114.000216 · DOI · Paper page
  24. 10.1016/j.numecd.2014.06.010 · DOI
  25. 10.1152/ajpgi.00303.2004 · DOI · Paper page
  26. 10.1194/jlr.P900015-JLR200 · DOI · Paper page
  27. 10.1186/1475-2840-13-49 · DOI · Paper page
  28. 10.2174/1570161113666150615111951 · DOI
  29. 10.4065/mcp.2009.0517 · DOI

Cited by

Metadata

Authors
Engelbrechtsen, L., Lundgren, J., Wewer Albrechtsen, N. J., Mahendran, Y., Iepsen, E. W., Finocchietto, P., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T., & Torekov, S. S.
Venue
Obesity Science & Practice
Publisher
Wiley
Published
2017-11-21
Volume
3
Issue
4
Pages
425-433
ISSN
2055-2238 (ISSN-L)
OpenAlex
W2751664507
Cited by
31
References
16
FWCI
1.67
Type
journal article
Language
en
Open access
gold
Funders
  • The Danish Research Council for Health and Disease (ref. no: 11-107683, 11-107683)
  • The Lundbeck Foundation
  • The P Carl Petersen Foundation
  • Tripartite Immunometabolism Consortium [TrIC]- Novo Nordisk Foundation (NNF15CC0018486)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.